Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the PDE6B gene.
Features include always present findings: Bone spicule pigmentation of the retina, Nyctalopia, Cataract, and Abnormal light- and dark-adapted electroretinogram and others. 6 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Cataract, Attenuation of retinal blood vessels |
PDE6B function has not been fully characterized.
Retinitis pigmentosa 40 is associated with mutations in the PDE6B gene on chromosome 4.
Genetic testing for PDE6B is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 40 has been reported in the published literature.
Phenotype severity distribution: 5 always present features.
No clinical trials have been registered for retinitis pigmentosa 40.
134 publications have been identified in PubMed for retinitis pigmentosa 40. Kisho has analyzed 105 by research type. Research spans Epidemiology / Natural History (35%), Basic Science / Preclinical (21%), and Case Report / Case Series (11%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 37 | 35% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 6:55 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
1 |
Bone spicule pigmentation of the retina |
Age of onset: adulthood.
Laboratory research |
22 |
21% |
Patient case studies | 12 | 11% |
Testing and diagnosis research | 11 | 10% |
Research summaries | 10 | 10% |
Clinical study results | 7 | 7% |
New treatment approaches | 6 | 6% |
Hong Y (2026). [PMID: 41242591](https://pubmed.ncbi.nlm.nih.gov/41242591/). *Am J Ophthalmol*. [Epidemiology / Natural History]
Marsh K (2026). [PMID: 41697461](https://pubmed.ncbi.nlm.nih.gov/41697461/). *Pharmacoecon Open*. [Basic Science / Preclinical]
Emanuelli A (2026). [PMID: 41826528](https://pubmed.ncbi.nlm.nih.gov/41826528/). *Doc Ophthalmol*. [Basic Science / Preclinical]
Brunet AA (2026). [PMID: 41562848](https://pubmed.ncbi.nlm.nih.gov/41562848/). *Pathophysiology*. [Basic Science / Preclinical]
Muto K (2026). [PMID: 41933129](https://pubmed.ncbi.nlm.nih.gov/41933129/). *Sci Rep*. [Epidemiology / Natural History]
Karuntu JS (2026). [PMID: 40530429](https://pubmed.ncbi.nlm.nih.gov/40530429/). *Acta Ophthalmol*. [Gene Therapy / Novel Therapeutics]
Theunis M (2026). [PMID: 41126390](https://pubmed.ncbi.nlm.nih.gov/41126390/). *Ophthalmic Genet*. [Review / Meta-Analysis]
Matsuo T (2026). [PMID: 41970067](https://pubmed.ncbi.nlm.nih.gov/41970067/). *Cureus*. [Case Report / Case Series]
Chandler LC (2026). [PMID: 41380951](https://pubmed.ncbi.nlm.nih.gov/41380951/). *Exp Eye Res*. [Basic Science / Preclinical]
Barthelemy N (2026). [PMID: 42011331](https://pubmed.ncbi.nlm.nih.gov/42011331/). *Am J Ophthalmol Case Rep*. [Case Report / Case Series]